T.N. KHALFINA, G.I. NURULLINA, A.A. SHAIHUTDINOVA, E.R. ABDULLINA, G.R. LOTFULLINA, D.M. SHAIDULLINA

 Republic Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan

Contact details:

Khalfina T.N. — PhD (medicine), Assistant Lecturer of the Department of Hospital Therapy

Address: 138 Orenburgskiy trakt, Kazan, Russian Federation, 420064, tel.: +7 (843) 237-31-89, e-mail: Tamila_khalfina@mail.ru

 Patients with immune-inflammatory diseases (IID) are a special group of patients at risk of infectious diseases with a probability of a more severe course and outcome. This problem has become more urgent with the emergence of a new coronavirus infection (NCVI) and the need for vaccination against COVID-19.

The purpose — to study the features of vaccination against COVID-19 in patients with immune-inflammatory diseases (IID).

Material and methods. Conducting surveys and interviews with rheumatological and nephrological patients about vaccination against COVID-19.

Results. The study included 225 patients with IID of the Nephrology and Rheumatology Departments of the Republic Clinical Hospital aged 18 to 82 years, among them 133 women and 92 men. Among the 133 women surveyed, 76 (57%) were vaccinated; the main reasons for refusing vaccination were high IID activity and previous NCVI. Among the 92 men surveyed, 59 (64%) were also vaccinated. Just like in women, the main reasons for refusal were high IID activity and previous NCVI.

Conclusions. Rheumatological and nephrological patients in general have a rather high (59%) commitment to vaccination against COVID-19. Patients over 35 y.o. were more committed. The main reasons for refusing to be vaccinated were medical withdrawal due to a high activity of the underlying disease and a recent NCVI. In this group of patients, vaccination against COVID-19 was effective and safe; there were no cases of NCVI within 6 months after vaccination.

Key words: immunoinflammatory diseases, vaccination, COVID-19.

REFERENCES

1. Belov B.S., Murav’eva N.V., Baranova M.M. Anti-inflammatory drugs and immunogenicity of vaccines in patients with rheumatic diseases. Meditsinskiy Sovet, 2021, no. 19, pp. 177–187 (in Russ.).
2. Au K., Reed G., Curtis J.R. et al. High disease activity is associated with an increased risk ofpatients with rheumatoid arthritis. Ann. Rheum. Dis, 2011, vol. 70 (5), pp. 785–791.
3. Belov B.S., Lila A.M. COVID-19 and rheumatology: a year later. Nauchno-prakticheskaya revmatologiya, 2021, vol. 59, no. 1, pp. 31–36 (in Russ.).
4. Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol, 2020, vol. 217. DOI: 10.1016/j.clim.2020.108480
5. Bengtsson C., Kapetanovic M.C., KKllberg H. et al. EIRA Study Group. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis, 2010, vol. 69 (10), pp. 1831–1833. DOI: 10.1136/ard.2010.129908
6. van Assen S., Agmon-Levin N., Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis, 2011, vol. 70, pp. 414–422.
7. Bukhanova D.V., Belov B.S., Tarasova G.M. et al. Comorbid infections in rheumatic diseases (according to V.A. Nasonova Research Institute). Meditsinskiy sovet, 2019, vol. 9, pp. 86–91 (in Russ.).
8. Curtis J.R., Johnson S.R., Anthony D.D. et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol, 2022, May, vol. 74 (5), pp. e21–e36. DOI: 10.1002/art.42109
9. Nasonov E.L., Lila A.M., Mazurov V.I. et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases. Recommendations of the All-Russian Public Organization «Association of Rheumatologists of Russia». Nauchno-prakticheskaya revmatologiya, 2021, vol. 59, no. 3, pp. 239–254 (in Russ.). Doi: 10.47360/1995-4484-2021-239-254
10. Belov B.S., Muravyeva N.V., Kulikov A.N. Immunogenicity of vaccines against SARS-CoV-2 in patients with rheumatic diseases. Antibiotics and Chemotherapy, 2022, vol. 67, pp. 5–6, 70–80. DOI: 10.37489/0235-2990-2022-67-5-6-70-80